If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
=== Cape Colony === In parts of Cape Colony, particularly the Cape Midlands District where Boers formed a majority of the white inhabitants, the British had always feared a general uprising against them. In fact, no such uprising took place, even in the early days of the war when Boer armies had advanced across the Orange. The cautious conduct of some elderly Orange Free State generals had been one factor that discouraged the Cape Boers from siding with the Boer republics. Nevertheless, there was widespread pro-Boer sympathy. Some Cape Dutch volunteered to help the British, but a larger number volunteered to help the other side. Politics was more important than the military factor: the Cape Dutch, according to Milner 90 percent of whom favoured the rebels, controlled the provincial legislature, and its authorities forbade the British Army to burn farms or to force Boer civilians into concentration camps. The British had more limited options to suppress the insurgency in the Cape Colony as result. After he escaped across the Orange in March 1901, de Wet had left forces under Cape rebels Kritzinger and Gideon Scheepers to maintain a guerrilla campaign in the Cape Midlands. The campaign here was one of the least chivalrous of the war, with intimidation by both sides of each other's civilian sympathisers. In one of many skirmishes, Commandant Johannes Lötter's small commando was tracked down by a much-superior British column and wiped out at Groenkloof.
==== MeSH D12.125.837 – serine ==== MeSH D12.125.837.075 – azaserine MeSH D12.125.837.150 – cycloserine MeSH D12.125.837.225 – droxidopa MeSH D12.125.837.300 – enterobactin MeSH D12.125.837.800 – phosphoserine
=== Polycythemia in neonates === Polycythemia in newborns is defined as hematocrit > 65%. Significant polycythemia can be associated with blood hyperviscosity, or thickening of the blood. Causes of neonatal polycythemia include:
Muscle cramping The cause of cramping is unknown, but may be related to elevated lactate, increased calcium signaling across the sarcoplasmic reticulum caused by membrane instability from reduced levels of ATP, or increased levels of free adenosine. Muscle weakness Muscle weakness is not a major symptom, though the progressive effects of chronic muscle damage from rhabdomyolysis will eventually cause significant weakness. Similarly, the long-term metabolic effects may result in nerve damage.
Sources: en.wikipedia.org
With increasing kidney damage, the autoregulation of renal blood flow, which normally ensures that the blood flow and thus the filtering capacity up to a threshold of 60 mm Hg are independent of the general blood pressure, is also impaired. As a result, kidney performance is reduced at low blood pressure and, in the case of high blood pressure often associated with chronic kidney disease, further damage occurs due to pressure overload of the renal corpuscles. The increase in blood pressure is due to hardening of the blood vessels in the area of the renal corpuscles, the reduced formation of vasodilating prostaglandins and activation of the renin-angiotensin-aldosterone system.
== Side effects == DOx drugs like DOM have been associated with certain side effects that have not occurred to the same extent with other psychedelics like LSD. Examples of such side effects include physical symptoms like sweating, tremors, and large increases in heart rate.
The F1 portion of ATP synthase is hydrophilic and responsible for hydrolyzing ATP. The F1 unit protrudes into the cytoplasm (matrix and stroma in mitochondria and chloroplasts respectively). Subunits α and β make a hexamer with 6 binding sites. Three of them are catalytically inactive and they bind ADP. Three other subunits catalyze the ATP synthesis. The other F1 subunits γ, δ, and ε are a part of a rotational motor mechanism (rotor/axle). The γ subunit allows β to go through conformational changes (i.e., closed, half open, and open states) that allow for ATP to be bound and released once synthesized. The F1 particle is large and can be seen in the transmission electron microscope by negative staining. These are particles of 9 nm diameter that pepper the inner mitochondrial membrane.
Pituitary prolactin is controlled by the Pit-1 transcription factor, which binds to the gene at several sites including a proximal promoter. This promoter is inhibited by dopamine and stimulated by estrogens, neuropeptides, and growth factors. Estrogens can also suppress dopamine. Interaction with neuropeptides is still a matter of active research: no specific prolactin-releasing hormone has been identified. It is known that mice react to both VIP and TRH, but humans seem to only react to TRH. There are prolactin-releasing peptides that work in vitro, but whether they deserve their name has been questioned. Oxytocin does not play a large role. Mice without a posterior pituitary do not raise their prolactin levels even with suckling and oxytocin injection, but scientists have yet to identify which specific hormone produced by this region is responsible. In birds (turkeys), VIP is a powerful prolactin-releasing factor, while peptide histidine isoleucine has almost no effect.
Erythromycin, Mitemcinal and related antibiotics act as non-peptide motilin agonists, and are sometimes used for their ability to stimulate gastrointestinal motility. In the case of erythromycin, it is its hemiketal intermediate, formed after an oral dose in the low-pH environment of the stomach lumen, which directly acts on the motilin receptor. Administration of a low dose of erythromycin will induce peristalsis, which provides additional support for the conclusion that motilin secretion triggers this pattern of gastrointestinal motility, rather than results from it. However, some of erythromycin's properties, including antibiotic activity, are not appropriate for a drug designed for chronic use over a patient's lifetime. New motilin agonists are erythromycin-based; however, it may be that this class of drugs becomes redundant. Growth hormone secretagogue receptors share 52% of their DNA with motilin receptors, and agonists of these receptors, termed ghrelins, can bring about similar effects to motilin agonists. Camicinal is a motilin agonist under development. Xylitol ingestion also increases motilin secretion, which may be related to xylitol's ability to cause diarrhea.
Sources: en.wikipedia.org
=== Chemical === The chemistry of nobelium is incompletely characterized and is known only in aqueous solution, in which it can take on the +3 or +2 oxidation states, the latter being more stable. It was largely expected before the discovery of nobelium that in solution, it would behave like the other actinides, with the trivalent state being predominant; however, Seaborg predicted in 1949 that the +2 state would also be relatively stable for nobelium, as the No2+ ion would have the ground-state electron configuration [Rn]5f14, including the stable filled 5f14 shell. It took nineteen years before this prediction was confirmed. In 1967, experiments were conducted to compare nobelium's chemical behavior to that of terbium, californium, and fermium. All four elements were reacted with chlorine and the resulting chlorides were deposited along a tube, along which they were carried by a gas. It was found that the nobelium chloride produced was strongly adsorbed on solid surfaces, proving that it was not very volatile, like the chlorides of the other three investigated elements. However, both NoCl2 and NoCl3 were expected to exhibit nonvolatile behavior and hence this experiment was inconclusive as to what the preferred oxidation state of nobelium was. Determination of nobelium's favoring of the +2 state had to wait until the next year, when cation-exchange chromatography and coprecipitation experiments were carried out on around fifty thousand 255No atoms, finding that it behaved differently from the other actinides and more like the divalent alkaline earth metals.
Mental disorders are diagnosed in accordance with diagnostic manuals such as the International Classification of Diseases (ICD), edited by the World Health Organization (WHO), and the Diagnostic and Statistical Manual of Mental Disorders (DSM), published by the American Psychiatric Association (APA). The fifth edition of the DSM (DSM-5) was published in May 2013. However, its release coincided with a statement by then-NIMH (National Institute of Mental Health) director Thomas Insel noting that the manual lacks validity compared to other medical specialties due to the absence of objective laboratory measures (biomarkers) for diagnosis. Treatment may include psychotropics (psychiatric medicines), psychotherapy, substance-abuse treatment, and other modalities such as interventional approaches, assertive community treatment, community reinforcement, and supported employment. Treatment may be delivered on an inpatient or outpatient basis, depending on the severity of functional impairment or risk to the individual or community. Research within psychiatry is conducted by psychiatrists on an interdisciplinary basis with other professionals, including clinical psychologists, epidemiologists, nurses, social workers, and occupational therapists. Psychiatry has been controversial since its inception, facing criticism both internally and externally over its medicalization of mental distress, reliance on pharmaceuticals, use of coercion, influence from the pharmaceutical industry, and its historical role in social control and contentious treatments.
(2026) determine the distribution of habitats suitable for Neanderthals and modern humans in Europe during stadial and interstadial events of Marine Isotope Stage 3, providing evidence of a shift but not complete disappearance of habitats suitable for Neanderthals as a result of climate changes, weak connectivity between optimal regions for Neanderthals, and overlaps between optimal regions of the two hominins. A Neanderthal infant assigned to the 6- to 14-month age range, providing evidence of rapid somatic growth in early life of Neanderthals, is described from the Amud Cave (Israel) by Been et al. (2026). Blinkhorn et al. (2026) study the variability of Levallois blanks from northeast Africa and southwest Asia, and interpret Levallois stone tools from northern Arabia dating to early Marine Isotope Stage 3 as likely produced by Neanderthals. Evidence from the study of palynological assemblages from the Axlor site (Spain), indicative of marked shifts in landscape structure at the time of the Neanderthal occupation of the site, is presented by Pérez-Díaz et al. (2026). Evidence of short-term Neanderthal occupations of the Eirós cave (Spain), indicative of high mobility of late Neanderthal communities from northwestern Iberian Peninsula, is presented by Rodríguez-Álvarez et al. (2026). Fotiadou et al.
On 15 April 2023, the country's paramilitary Rapid Support Forces launched attacks against al-Burhan's government, claiming to capture key government sites. Al-Burhan claimed these sites were still under the control of his forces, and that fighting was ongoing. The clashes continued until at least 21 April with occasional ceasefires. Al-Burhan was pinned down at SAF headquarters in Khartoum until August 2023, when a military operation enabled him to evacuate to Port Sudan, where he has been based since then. The Sudanese military allegedly received support from Ukraine. Ukraine has also allegedly sent troops to fight in Omdurman. Their rival, the Rapid Support Forces, had reportedly received support from Libya and the United Arab Emirates as well as Russia's Wagner Group. The foreign involvement in the regional war could have a devastating effect on Sudan. Al-Burhan survived an assassination attempt while attending a military graduation ceremony in Gebeit, in July 2024. Five people were killed in the drone attack. In August 2025, a military official in Sudan confirmed that al-Burhan's envoy, Al-Sadiq Ismail, visited Israel in a push to speed the process of formal normalization between both countries through the Abraham Accords, which has been delayed due to the war. It was reported that Sudan wanted Israeli support following the capture of Khartoum by the SAF in exchange for Sudan's recognition.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.